NBIX Neurocrine Biosciences Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: NBIX
  4. Earnings
?
Relative Growth: Rel. Growth: 99
Relative Strength: Rel. Strength: 67
Relative Valuation: Rel. Valuation: 66
Relative Profitability: Rel. Profitability: 98

EPS in 2026 (TTM): $6.71

Last Report Period Date: Mar 31, 2026

As of June 2026, NBIX's current EPS stands at $6.71, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of $4.81, which marks an increase compared to its EPS of $3.4 in 2024. NBIX reported an EPS of $1.97 for the quarterly report ending on Mar 31, 2026.

NBIX earnings history

Historical annual and quarterly earnings per share (EPS) data for Neurocrine Biosciences
EPS (TTM)
$6.71
EPS Growth YoY (Quarterly)
2,362.5%
EPS (Quarterly)
$1.97
EPS Growth (Quarterly)
27.9%

For 2025, Neurocrine Biosciences's EPS was $4.81, an increase of 41.5% from $3.4 in 2024. For the fiscal quarter that ended on Mar 31, 2026, the per-share earnings was $1.97, showing a 2,362.5% increase from the same quarter last year. For the twelve months ending March 2026, the EPS is $6.71. For the year 2024, the yearly earnings per share was $3.4, marking an increase of 32.8% from 2023.

NBIX earnings chart

NBIX EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
2,362.5%
EPS growth YoY
41.5%
EPS growth 3Y avg
44%
EPS growth 5Y avg
1.9%

During the last 12 months, Neurocrine Biosciences has seen an EPS growth of 2,362.5% (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of 44% per year for the last three years. During the last 5 years, the company had an average EPS growth rate of 1.9%.

NBIX Earnings Waterfall

Breakdown of revenue, profit and net income for Neurocrine Biosciences

NBIX Earnings vs Peers

What are the earnings of NBIX compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
PFE Pfizer Inc 18.87 -3.5% -37.4% -3.7%
ANIP Ani Pharmaceuticals Inc 20.18 436.5% N/A N/A
NBIX Neurocrine Biosciences Inc 24.06 41.5% 44% 1.9%
RPRX Royalty Pharma plc 28.98 -6.8% 161.6% 6.3%
LLY ELI LILLY & Co 39.27 95.6% 49.2% 27.5%
ABBV AbbVie Inc 115.65 -1.3% -29.1% -2.8%
RGEN Repligen Corp 137.36 289.1% -36.2% -5.3%

All data is based on quarterly TTM periods, unless otherwise specified.